Skip to main content
. Author manuscript; available in PMC: 2021 Jan 8.
Published in final edited form as: Leukemia. 2020 Apr 16;35(1):189–200. doi: 10.1038/s41375-020-0810-4

Fig.6.

Fig.6.

Graphical representation of the proposed mechanism of action of Dara, showing that anti-CD38 targeting induces NK cell activation and degranulation and leads to increased expression of CD80/CD86 T cell costimulatory molecules on monocytes, which induces monocyte polarization and activation and stimulates T cell expansion through CD28 binding, further associated with an immune cascade targeting CD38+ MM cells.